| 1966 |
A possible method for estimation of Bisphenol-A |
| 1967 |
Epoxy-BPA |
| 1967 |
Kinetics BPA Formation |
| 1967 |
TLC BPA |
| 1968 |
Estimation of Diglycidyl Ether in Epoxide Resins |
| 1980 |
Penicillins |
| 1980 |
Vitamin A |
| 1981 |
Drugs and Pharma Industry Highlights |
| 1981 |
Generics Policy And Drugs I-Approach to implementation |
| 1981 |
Intermediates and bulk drugs production – Sixth Plan |
| 1982 |
Helical Coil Heat Exgr |
| 1982 |
Pharma Industry in India |
| 1984 |
Guidelines for Entrepreneurs |
| 1985 |
Rifampicin Global Status |
| 1988 |
Local Anaesthetics |
| 1988 |
Production of Therapeutic Polypeptides |
| 1991 |
Microbial Gene Technology |
| 1991 |
Recomb Ecoli |
| 1992 |
Indian scenario on medical diagnostics business |
| 1992 |
Biotechnology industries in India: Investment Opportunities |
| 1992 |
Prospects of Biotech Industry India Human Animal |
| 1992 |
Study of Diagnostics Market in India |
| 1993 |
Endowment Lecture TNVAS |
| 1994 |
Govt regulations licensing and approvals for the biotech industry |
| 1995 |
Biotechnology and Development Review |
| 1995 |
Indust Policy TRIPS Biotech |
| 1996 |
Commercializing Indian Biotechnologies |
| 1996 |
MIcrobial LIPASES |
| 1997 |
GM Plants Ind Agri |
| 1997 |
Transgenic plants and biosafety concerns in India |
| 1998 |
Indian Penicillin Industry Turbulence Ahead Part I and II |
| 1998 |
pH and Thermo sensitive nanoparticles |
| 1999 |
Consultancy and its relevance to Biotechnology in India |
| 1999 |
Strategies for manipulation of genes beta lactam antibiotics |
| 1999 |
US PATENT Nano particles 5874111 Monodisperse Nanoparticles |
| 1999 |
US5874111 |
| 2000 |
Indian Rules, Regulations and Procedures for handling Transgenic Plants |
| 2000 |
GM Crops in India with special reference to Cotton |
| 2000 |
A Journey from the Kingdom of Chemistry to the land of Biotechnology |
| 2000 |
Biodistribution of Dextran |
| 2000 |
GM Crops update Gen Art New India Digest NEW |
| 2000 |
Hydrophillic-nanoparticles IJBB 37-5- 273-282 |
| 2000 |
Recent Advances in synthesis of modified oligonucleotides |
| 2001 |
Prospects for Biotechnology in India |
| 2001 |
Bt-Cotton Govt Procedures |
| 2001 |
GM Crops Benefits Debate Economic Times |
| 2001 |
IPR Issues in Biotechnology India |
| 2001 |
PKG Article in The Hindu |
| 2001 |
US PKG 6322817 Paclitaxel |
| 2001 |
US6322817 |
| 2002 |
Commercialization and assessment of a rapid hiv antibody detection kit |
| 2003 |
RFecent advances in ogilonucleotide synthesis Indain J Biochem And Biophy |
| 2003 |
Rules GMOs India |
| 2004 |
Comparative-evaluation of rapid and elisa kits for detection of hiv infection |
| 2004 |
Role of allaince in modern biotech industries |
| 2005 |
Comment on activity of commercial Strepto |
| 2007 |
Accelerated composting of coir pith |
| 2007 |
Advance in Biopharma INDIA REPRINT Chapter 1 |
| 2007 |
GM FOOD SAFETY VAK |
| 2007 |
GM-CSF Review |
| 2007 |
Human GM-CSF Review |
| 2007 |
Sodium hyaluronate of defined osteoarthritis |
| 2007 |
Induction of resistance in tea plants against root rot pathogens |
| 2007 |
Bring rational regulatory regime for rDNA biotech products-The Economic Times |
| 2008 |
Cadila Patent Mw 10 583 731 Vaccine Adjuvants p38 inhibitors |
| 2008 |
Indian Efforts Biotech development |
| 2008 |
Adv Biopharma Industry India Chap 1 Book |
| 2010 |
Probiotic assisted colon specifc delivery |
| 2011 |
Would healing potential of Apamarga leaves |
| 2013 |
Phyto Extracts in Wound Healing |
| 2014 |
Effects of probiotics addition and shellac coating from guar gum matrix tablets |
| 2015 |
Predictive Perspectives of Disease—Transformed Protein Biomarkers |
| 2016 |
Similar Biologics: Global Opportunities and Issues |
| 2017 |
Identity Preservation System for LMOs in India-Feasibility Issues |
| 2019 |
Policies and Growth of Pharmaceutical Industry in India-A Review |
| 2019 |
Human Vaccines in India: Present and Future Perspectives |
| 2020 |
Human vaccines industry in China, 2019: Part—I |
| 2020 |
Human vaccines industry in China, 2019: Part II |
| 2020 |
Human vaccines industry in China, 2019: Part III |
| 2020 |
Tuberculosis-prone countries and resistance to COVID-19 |
| 2020 |
Effective SARS-CoV-2 Vaccines on the Horizon |
| 2020 |
Utility of convalescent plasma for COVID-19 treatment |
| 2021 |
Novel Active Pharmaceutical Ingredients from India: The Actors-Part-I |
| 2021 |
Novel active pharmaceutical ingredients from India: The issues—Part-II |
| 2021 |
Generation of efficacy data on 60 years and older population using SARS-CoV-2 vaccines |
| 2021 |
Global efforts on vaccines development against SARS-CoV-2 and Indian endeavor |
| 2022 |
Exploring clues for wide variations in COVID-19 fatality rates among countries |
| 2022 |
Infectious human diseases: Regions, habitats, threats, and mitigation strategies: The actors—Part I |
| 2023 |
Infectious human diseases: : The issues -Part II |
| 2023 |
Status of Indian Biopharmaceutical Industry |
| 2023 |
Tuberculosis control by novel vaccines development and Indian initiatives |
| 2023 |
Bioeconomy |
